At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
migalastat HCldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multiple Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Female Patients With Fabry Disease
In Brief
A Phase 2 clinical trial evaluating migalastat HCl for Fabry Disease. Completed, enrolled 9 participants across 6 sites in 6 countries.
Detailed Summary
Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFabry Disease
CountriesAustralia, Brazil, Canada, France, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2006
Enrollment StartSep 2006
Primary CompletionMay 2008
TodayJul 2026
First PostedMar 20, 2006
Enrollment StartSep 7, 2006
Primary CompletionMay 9, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.3 years ago
Interventions
migalastat HCldrug